Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P28221

UPID:
5HT1D_HUMAN

ALTERNATIVE NAMES:
Serotonin 1D alpha receptor; Serotonin receptor 1D

ALTERNATIVE UPACC:
P28221

BACKGROUND:
The Serotonin receptor 1D, identified by its UPACC code P28221, serves as a critical receptor for serotonin and ergot alkaloid derivatives, impacting various physiological processes. By modulating adenylate cyclase activity through G protein signaling, it plays a significant role in the brain's serotonin release and neural activity regulation, with implications for neurotransmitter release beyond serotonin.

THERAPEUTIC SIGNIFICANCE:
Exploring the Serotonin receptor 1D's function offers a pathway to novel therapeutic approaches. Its key role in neurotransmission and potential impact on vasoconstriction positions it as a valuable target for drug discovery in neurological and vascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.